相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。
Article
Oncology
Firas Hamdan et al.
Summary: Immune checkpoint inhibitors have shown clinical success in cancer treatment, but there is room for improvement. Researchers have developed an oncolytic adenovirus, Ad-Cab, to enhance the efficacy of PD-L1 checkpoint inhibitors. By adding somatic mutations to increase natural killer (NK) cell activation, they further improved the effectiveness of the therapy. The modified adenovirus demonstrated targeted release in the tumor microenvironment and better tumor killing.
MOLECULAR THERAPY-ONCOLYTICS
(2023)
Article
Immunology
Noy Cohen Saban et al.
Summary: This study investigated the antitumor activity of FDA-approved anti-PD-L1 monoclonal antibodies (mAbs) and their interaction with Fc gamma receptors (Fc gamma Rs). The results showed that both wild-type and Fc-mutated IgG scaffolds of anti-PD-L1 mAbs displayed similar antitumor efficacy in mice. However, the antitumor activity of the wild-type mAb was enhanced when combined with an Fc gamma RIIB-blocking antibody. Furthermore, glycoengineering of the mAb to enhance its binding to activating Fc gamma RIIIA also increased its antitumor activity. These findings suggest strategies to optimize anti-PD-L1 immunotherapy by enhancing Fc gamma R engagement.
SCIENCE IMMUNOLOGY
(2023)
Review
Oncology
Rui Ma et al.
Summary: Oncolytic viruses offer potential as a novel therapy for cancer patients resistant to traditional treatments. They can directly kill tumor cells and activate an immune response, while sparing normal cells. However, challenges such as limited tumor penetration, short persistence, and the host immune response hinder the clinical translation of oncolytic virotherapy. Overcoming these challenges could lead to powerful combination therapies, such as oncolytic viruses plus immune checkpoint blockade or CAR-based immunotherapies.
Article
Oncology
Hong-My Nguyen et al.
Summary: Anti-PD-1 therapy and oncolytic viruses (OVs) have different mechanisms in fighting against tumors. OVs can enhance the effectiveness of anti-PD-1 therapy by reversing immunosuppressive factors and increasing the number of infiltrating lymphocytes. The timing of administration of the two agents is crucial for optimal therapeutic success, with the most promising approach being OV lead-in followed by concurrent therapy.
SEMINARS IN CANCER BIOLOGY
(2022)
Review
Oncology
Marti Farrera-Sal et al.
Summary: Cancer immunotherapy utilizing immune checkpoint inhibitors has shown effectiveness in various human cancers, but cold tumors often lack immune cells and are typically unresponsive. Oncolytic viruses, with their lytic and immunogenic mechanisms, have attracted interest as potential therapeutic approaches to heat or promote lymphocyte infiltration of cold tumors. This article reviews the use of oncolytic adenoviruses in cancer immunotherapy, focusing on immune responses triggered by these viruses against tumor antigens in preclinical and clinical settings, as well as considerations for clinical trial design and combination therapies with conventional treatments or other immunotherapies.
CLINICAL CANCER RESEARCH
(2021)
Review
Oncology
Li-Chung Tsao et al.
Summary: Monoclonal antibodies are a crucial component of cancer therapy, primarily working by stimulating innate immune effector processes. Different therapeutic mAbs targeting various tumor antigens have shown significant efficacy, with a key role of innate immune-mediated mechanisms observed in mAb therapies against different types of cancer, including HER2(+) solid tumors.
Article
Oncology
Rony Dahan et al.
Article
Oncology
Arianne M. Brandsma et al.
CANCER IMMUNOLOGY RESEARCH
(2015)
Review
Biotechnology & Applied Microbiology
Stephen J. Russell et al.
NATURE BIOTECHNOLOGY
(2012)
